[Form 4] BioAge Labs, Inc. Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
BioAge Labs, Inc. principal accounting officer Shane Barton exercised stock options and sold shares of common stock in late June. He exercised options covering 59,934 shares at strike prices between $4.30 and $10.85 per share, then sold a total of 62,566 shares in open-market transactions at weighted average prices around $25 per share. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025, and after these trades he reported holding no shares of common stock directly.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 62,566 shares ($1,576,752)
Net Sell
18 txns
Insider
Barton Shane
Role
Principal Accounting Officer
Sold
62,566 shs ($1.58M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 4,290 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 4,000 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 4,065 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 7,861 | $0.00 | -- |
| Exercise | Common Stock | 4,290 | $10.85 | $47K |
| Exercise | Common Stock | 4,000 | $8.39 | $34K |
| Exercise | Common Stock | 4,065 | $4.30 | $17K |
| Exercise | Common Stock | 7,861 | $4.38 | $34K |
| Sale | Common Stock | 20,216 | $25.1868 | $509K |
| Exercise | Stock Option (Right to Buy) | 9,301 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 7,261 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 8,958 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 14,198 | $0.00 | -- |
| Exercise | Common Stock | 9,301 | $10.85 | $101K |
| Exercise | Common Stock | 7,261 | $8.39 | $61K |
| Exercise | Common Stock | 8,958 | $4.30 | $39K |
| Exercise | Common Stock | 14,198 | $4.38 | $62K |
| Sale | Common Stock | 42,350 | $25.2084 | $1.07M |
Holdings After Transaction:
Stock Option (Right to Buy) — 13,299 shares (Direct, null);
Common Stock — 4,290 shares (Direct, null)
Footnotes (1)
- The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.79 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.42 per share, inclusive. The option vested as to 1/4th of the total award on September 25, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. The option vested as to 1/4th of the total award on October 17, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. The option vested as to 1/4th of the total award on October 26, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
